The LiBBY trial (Life's End Benefits of THC and CBD) tested an oil for late-stage dementia agitation and lowered scores through 12 weeks. That benefit is established only as early Phase 2 findings in hospice-eligible patients, so the formula remains experimental. According to the Alzheimer's Association, the study was an NIH-funded Phase 2 randomized, double-blind, placebo-controlled trial in 120 hospice-eligible patients with clinically significant agitation AAIC meeting release. It was reported July 14, 2026, at AAIC London.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did patients take?
- How much did agitation improve?
- Who was studied at home?
- What did safety show?
- What should spouses discuss next?
What did patients take?
Participants received a novel oral oil called T2:C100. It contained 2 mg THC plus 100 mg CBD twice daily for 12 weeks.
The comparison group received matching placebo. Both groups continued routine physician care during the 12 weeks.
How much did agitation improve?
Treatment met its early endpoint at week 2. Cohen-Mansfield Agitation Inventory scores, a checklist rating restlessness and aggressive behaviors, fell 6.27 points more with THC/CBD than with placebo.
Urban Health Today reported that gap lasted through week 12 home-based THC and CBD trial report. By week 12, clinicians rated overall improvement in 87.2% of treated patients versus 23.6% with placebo, or nearly 9 in 10 improving.
Who was studied at home?
The trial focused on the spouses' and partners' situation. Mean age was about 80, 55% were women, and 58% were from historically underrepresented groups.
Most lived outside nursing homes. About 75% lived in community settings and received home visits, which matches late-stage care given by a spouse or partner.
What did safety show?
Overall adverse-event rates were similar between groups. Serious adverse events occurred more often in the treatment arm.
Investigators judged those serious events unrelated to study medication. The pattern still matters because hospice-eligible patients carry high background illness and close monitoring is needed.
What should spouses discuss next?
Results are Phase 2 topline conference findings with an experimental formulation, according to the LiBBY Study site study FAQ. The oil has not been submitted for FDA approval and is not yet peer-reviewed, so larger trials are needed.
For spouses and partners, keep non-drug strategies first-line. Make any medication decision jointly with the hospice team and do not substitute dispensary cannabis for the trial oil.
You Might Also Like
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: What Is Established and What Remains Uncertain for Spouses and Partners
- Dementia With Multiple Etiologies in the 2026 NIA Report: Research Participation Questions for Spouses and Partners
- AAIC 2026 Primary Care Alzheimer’s Blood Test Findings: What Is Established and What Remains Uncertain for Memory Clinic Patients





